Effect of Platelet Function Testing Guidance on Clinical Outcomes for Patients with Intracranial Aneurysms Undergoing Endovascular Treatment

References

1. 1.↵
   1. Pierot L,
   2. Wakhloo AK

   . Endovascular treatment of intracranial aneurysms: current status. Stroke 2013;44:2046–54 doi:10.1161/STROKEAHA.113.000733 pmid:23798560

   FREE Full Text
2. 2.↵
   1. Molyneux AJ,
   2. Kerr RS,
   3. Yu LM, et al

   ; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet 2005;366:809–17 doi:10.1016/S0140-6736(05)67214-5 pmid:16139655

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Pierot L,
   2. Spelle L,
   3. Vitry F

   ; ATENA Investigators. Immediate clinical outcome of patients harboring unruptured intracranial aneurysms treated by endovascular approach: results of the ATENA study. Stroke 2008;39:2497–504 doi:10.1161/STROKEAHA.107.512756 pmid:18617659

   Abstract/FREE Full Text
4. 4.↵
   1. Thompson BG,
   2. Brown RD Jr.,
   3. Amin-Hanjani S, et al

   ; American Stroke Association. Guidelines for the Management of Patients with Unruptured Intracranial Aneurysms: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 2015;46:2368–400 doi:10.1161/STR.0000000000000070 pmid:26089327

   Abstract/FREE Full Text
5. 5.↵
   1. Li W,
   2. Zhu W,
   3. Wang A, et al

   . Effect of adjusted antiplatelet therapy on preventing ischemic events after stenting for intracranial aneurysms. Stroke 2021;52:3815–25 doi:10.1161/STROKEAHA.120.032989 pmid:34538087

   CrossRefPubMed
6. 6.↵
   1. Hwang G,
   2. Huh W,
   3. Lee JS, et al

   . Standard vs modified antiplatelet preparation for preventing thromboembolic events in patients with high on-treatment platelet reactivity undergoing coil embolization for an unruptured intracranial aneurysm: a randomized clinical trial. JAMA Neurol 2015;72:764–72 doi:10.1001/jamaneurol.2015.0654 pmid:26010803

   CrossRefPubMed
7. 7.↵
   1. Delgado Almandoz JE,
   2. Kadkhodayan Y,
   3. Crandall BM, et al

   . Variability in initial response to standard clopidogrel therapy, delayed conversion to clopidogrel hyper-response, and associated thromboembolic and hemorrhagic complications in patients undergoing endovascular treatment of unruptured cerebral aneurysms. J Neurointerv Surg 2014;6:767–73 doi:10.1136/neurintsurg-2013-010976 pmid:24353331

   Abstract/FREE Full Text
8. 8.↵
   1. Fifi JT,
   2. Brockington C,
   3. Narang J, et al

   . Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. AJNR Am J Neuroradiol 2013;34:716–20 doi:10.3174/ajnr.A3405 pmid:23194833

   Abstract/FREE Full Text
9. 9.↵
   1. Flechtenmacher N,
   2. Kämmerer F,
   3. Dittmer R, et al

   . Clopidogrel resistance in neurovascular stenting: correlations between light transmission aggregometry, VerifyNow, and the Multiplate. AJNR Am J Neuroradiol 2015;36:1953–58 doi:10.3174/ajnr.A4388 pmid:26272977

   Abstract/FREE Full Text
10. 10.↵
    1. Yang H,
    2. Li Y,
    3. Jiang Y

    . Insufficient platelet inhibition and thromboembolic complications in patients with intracranial aneurysms after stent placement. J Neurosurg 2016;125:247–53 doi:10.3171/2015.6.JNS1511 pmid:26587657

    CrossRefPubMed
11. 11.↵
    1. Favaloro EJ,
    2. Lippi G,
    3. Franchini M

    . Contemporary platelet function testing. Clin Chem Lab Med 2010;48:579–98 doi:10.1515/CCLM.2010.121 pmid:20148722

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Higashiguchi S,
    2. Sadato A,
    3. Nakahara I, et al

    . Reduction of thromboembolic complications during the endovascular treatment of unruptured aneurysms by employing a tailored dual antiplatelet regimen using aspirin and prasugrel. J Neurointerv Surg 2021;13:1044–48 doi:10.1136/neurintsurg-2020-016994 pmid:33632886

    Abstract/FREE Full Text
13. 13.↵
    1. Cheung NK,
    2. Carr MW,
    3. Ray U, et al

    . Platelet function testing in neurovascular procedures: tool or gimmick? Interv Neurol 2020;8:123–34 doi:10.1159/000496702 pmid:32508894

    CrossRefPubMed
14. 14.↵
    1. Kim GJ,
    2. Heo Y,
    3. Moon EJ, et al

    . Thromboembolic events during endovascular coiling for unruptured intracranial aneurysms: clinical significance of platelet reactivity unit and adjunctive cilostazol. Clin Neurol Neurosurg 2022;213:107133 doi:10.1016/j.clineuro.2022.107133 pmid:35065532

    CrossRefPubMed
15. 15.↵
    1. Moon EJ,
    2. Kwon B,
    3. Song Y, et al

    . The necessity of monitoring platelet response and adjusting antiplatelet agents for endovascular treatment of unruptured intracranial aneurysms: a single-center, retrospective, cohort study. In: Proceedings of the 14th Congress of the European Society of Minimally Invasive Neurological Therapy, September 2022, Nice, Provence-Alpes-Cote d Azur, France. doi:10.1136/neurintsurg-2022-ESMINT.10
16. 16.↵
    1. Aoun SG,
    2. Welch BG,
    3. Pride LG, et al

    . Contribution of whole platelet aggregometry to the endovascular management of unruptured aneurysms: an institutional experience. J Neurointerv Surg 2017;9:974–77 doi:10.1136/neurintsurg-2016-012623 pmid:27651476

    Abstract/FREE Full Text
17. 17.↵
    1. Brinjikji W,
    2. Lanzino G,
    3. Cloft HJ, et al

    . Platelet testing is associated with worse clinical outcomes for patients treated with the Pipeline Embolization Device. AJNR Am J Neuroradiol 2015;36:2090–95 doi:10.3174/ajnr.A4411 pmid:26251435

    Abstract/FREE Full Text
18. 18.↵
    1. Ajadi E,
    2. Kabir S,
    3. Cook A, et al

    . Predictive value of Platelet Reactivity Unit (PRU) value for thrombotic and hemorrhagic events during flow diversion procedures: a meta-analysis. J Neurointerv Surg 2019;11:1123–28 doi:10.1136/neurintsurg-2019-014765 pmid:31005859

    Abstract/FREE Full Text
19. 19.↵
    1. Skukalek SL,
    2. Winkler AM,
    3. Kang J, et al

    . Effect of antiplatelet therapy and platelet function testing on hemorrhagic and thrombotic complications in patients with cerebral aneurysms treated with the Pipeline Embolization Device: a review and meta-analysis. J Neurointerv Surg 2016;8:58–65 doi:10.1136/neurintsurg-2014-011145 pmid:25385746

    Abstract/FREE Full Text
20. 20.↵
    1. Gonzalez SM,
    2. Iordanou J,
    3. Adams W, et al

    . Effect of stent porosity, platelet function test usage, and dual antiplatelet therapy duration on clinical and radiographic outcomes after stenting for cerebral aneurysms: a meta-analysis. World Neurosurg 2023;171:159 doi:10.1016/j.wneu.2022.12.055 pmid:36529432

    CrossRefPubMed
21. 21.↵
    1. Moher D,
    2. Liberati A,
    3. Tetzlaff J, et al

    ; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535 doi:10.1136/bmj.b2535 pmid:19622551

    FREE Full Text
22. 22.↵
    1. Higgins JP,
    2. Altman DG,
    3. Gøtzsche PC, et al

    ; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928 doi:10.1136/bmj.d5928 pmid:22008217

    FREE Full Text
23. 23.↵
    1. Richardson M,
    2. Garner P,
    3. Donegan S

    . Interpretation of subgroup analyses in systematic reviews: a tutorial. Clin Epidemiol Glob Health 2019;7:192–98 doi:10.1016/j.cegh.2018.05.005

    CrossRef
24. 24.↵
    1. Oran I,
    2. Cinar C,
    3. Bozkaya H, et al

    . Tailoring platelet inhibition according to multiple electrode aggregometry decreases the rate of thrombotic complications after intracranial flow-diverting stent implantation. J Neurointerv Surg 2015;7:357–62 doi:10.1136/neurintsurg-2013-011023 pmid:24721755

    Abstract/FREE Full Text
25. 25.↵
    1. Li Y,
    2. Zhang X,
    3. Guo Z, et al

    . Standard vs. modified antiplatelet therapy based on thromboelastography with platelet mapping for preventing bleeding events in patients undergoing stent-assisted coil for a ruptured intracranial aneurysm. Front Neurol 2021;11:615829 doi:10.3389/fneur.2020.615829 pmid:33584516

    CrossRefPubMed
26. 26.↵
    1. Neyens R,
    2. Donaldson C,
    3. Andrews C, et al

    . Platelet function testing with a VerifyNow-directed personalized antiplatelet strategy and associated rates of thromboembolic complications after Pipeline embolization for complex cerebral aneurysms. World Neurosurg 2020;138:e674–82 doi:10.1016/j.wneu.2020.03.046 pmid:32194270

    CrossRefPubMed
27. 27.↵
    1. Koh JS,
    2. Hwang G,
    3. Park JC, et al

    ; KoNES Registry Investigators. Tailored antiplatelet therapy in stent assisted coiling for unruptured aneurysms: a nationwide registry study. J Neurointerv Surg 2023 Jan 3 [Epub ahead of print] doi:10.1136/jnis-2022-019571 pmid:36596671

    CrossRefPubMed
28. 28.↵
    1. Price MJ,
    2. Berger PB,
    3. Teirstein PS, et al

    ; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097–105 doi:10.1001/jama.2011.290 pmid:21406646

    CrossRefPubMedWeb of Science
29. 29.↵
    1. McTaggart RA,
    2. Choudhri OA,
    3. Marcellus ML, et al

    . Use of thromboelastography to tailor dual-antiplatelet therapy in patients undergoing treatment of intracranial aneurysms with the Pipeline Embolization Device. J Neurointerv Surg 2015;7:425–30 doi:10.1136/neurintsurg-2013-011089 pmid:24739599

    Abstract/FREE Full Text
30. 30.↵
    1. Wang Y,
    2. Meng X,
    3. Wang A, et al

    ; CHANCE-2 Investigators. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. N Engl J Med 2021;385:2520–30 doi:10.1056/NEJMoa2111749 pmid:34708996

    CrossRefPubMed
31. 31.↵
    1. Wang A,
    2. Meng X,
    3. Tian X, et al

    ; CHANCE-2 Investigators. Bleeding risk of dual antiplatelet therapy after minor stroke or transient ischemic attack. Ann Neurol 2022;91:380–88 doi:10.1002/ana.26287 pmid:34951042

    CrossRefPubMed
32. 32.↵
    1. Wang A,
    2. Meng X,
    3. Tian X, et al

    . Ticagrelor aspirin vs clopidogrel aspirin in CYP2C19 loss-of-function carriers with minor stroke or TIA stratified by risk profile. Neurology 2023;100:e497–504 doi:10.1212/WNL.0000000000201454 pmid:36535779

    CrossRefPubMed
33. 33.↵
    1. Pinto Slottow TL,
    2. Bonello L,
    3. Gavini R, et al

    . Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. Am J Cardiol 2009;104:525–30 doi:10.1016/j.amjcard.2009.04.015 pmid:19660606

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Bouman HJ,
    2. van Werkum JW,
    3. Breet NJ, et al

    . A case-control study on platelet reactivity in patients with coronary stent thrombosis. J Thromb Haemost 2011;9:909–16 doi:10.1111/j.1538-7836.2011.04255.x pmid:21382172

    CrossRefPubMed
35. 35.↵
    1. Kim KS,
    2. Fraser JF,
    3. Grupke S, et al

    . Management of antiplatelet therapy in patients undergoing neuroendovascular procedures. J Neurosurg 2018;129:890–905 doi:10.3171/2017.5.JNS162307 pmid:29192856

    CrossRefPubMed
36. 36.↵
    1. Sibbing D,
    2. Aradi D,
    3. Alexopoulos D, et al

    . Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv 262019;12:1521–37 doi:10.1016/j.jcin.2019.03.034 pmid:31202949

    Abstract/FREE Full Text